Accolade (ACCD) Stock Price

Accolade Price

Delisted·Apr 7, 2025
7.02USD
Last traded price

Over the last 6 years Accolade grew revenue by 33.2% annually, reaching 408.34 M USD. For Accolade, the net margin of -24.4% is up versus -39.6% a few years ago. The consensus 12-month price target for Accolade is 7.17 USD, about 2.1% above where the stock trades today. Of 18 analysts, 7 rate the stock a buy — an overall Hold consensus.

Accolade stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Accolade over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Accolade stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Accolade's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Accolade Stock Price History
DateAccolade Price
Access this data via the Eulerpool API

Accolade Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
307.12 M USD
-171.14 M USD
-123.12 M USD
Jan 1, 2023
363.14 M USD
135.90 M USD
-459.65 M USD
Jan 1, 2024
408.34 M USD
-114.45 M USD
-99.81 M USD
Jan 1, 2025 (e)
467.40 M USD
0.00 USD
-21.73 M USD
Jan 1, 2026 (e)
526.44 M USD
-101.65 M USD
-16.40 M USD
Jan 1, 2028 (e)
643.31 M USD
-53.98 M USD
8.36 M USD
Jan 1, 2029 (e)
805.80 M USD
23.46 M USD
0.00 USD
Jan 1, 2030 (e)
910.96 M USD
37.43 M USD
0.00 USD

Accolade Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 26, 2026, 10:05 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20182019202020212022202320242025e2026e2028e2029e2030e2031e
0.080.090.130.170.310.360.410.470.530.640.810.911.02
23.6840.4328.7982.3517.1014.0512.8012.6322.2425.1913.0412.20
30.2636.1743.9444.7145.4845.1846.3846.3846.3846.3846.3846.3846.38
23.0034.0058.0076.00141.00164.00192.00216.58243.94298.20373.33422.03473.51
-59.00-54.00-48.00-46.00-171.00135.00-114.00-101.00-53.0023.0037.00
-77.63-57.45-36.36-27.06-55.1637.19-27.54-19.20-8.242.864.07
-61.00-56.00-51.00-50.00-123.00-459.00-99.00-21.00-16.008.00
-8.20-8.93-1.96146.00273.17-78.43-78.79-23.81-150.00
4.835.7851.5871.4971.2376.1480.6580.6580.6580.6580.6580.6580.65
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Accolade generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Accolade retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Accolade's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Accolade has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Accolade's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Accolade stock margins

The Accolade margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Accolade. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Accolade.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
45.39 %
-37.28 %
-39.64 %
Jan 1, 2021
46.02 %
-28.16 %
-30.40 %
Jan 1, 2022
45.91 %
-55.73 %
-40.09 %
Jan 1, 2023
45.23 %
37.42 %
-126.58 %
Jan 1, 2024
47.03 %
-28.03 %
-24.44 %
Jan 1, 2025 (e)
47.03 %
0.00 %
-4.65 %
Jan 1, 2026 (e)
47.03 %
-19.31 %
-3.11 %
Jan 1, 2028 (e)
47.03 %
-8.39 %
1.30 %

Accolade Stock Revenue, EBIT, Earnings per Share

The Accolade earnings per share therefore indicates how much revenue Accolade has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
2.51 USD
-0.94 USD
-1.00 USD
Jan 1, 2021
2.33 USD
-0.66 USD
-0.71 USD
Jan 1, 2022
4.31 USD
-2.40 USD
-1.73 USD
Jan 1, 2023
4.77 USD
1.78 USD
-6.04 USD
Jan 1, 2024
5.06 USD
-1.42 USD
-1.24 USD
Jan 1, 2025 (e)
5.70 USD
0.00 USD
-0.27 USD
Jan 1, 2026 (e)
6.42 USD
-1.26 USD
-0.20 USD
Jan 1, 2028 (e)
7.85 USD
-0.67 USD
0.10 USD

Accolade business model & stock analysis

Accolade Inc is a US-American company based in Seattle. The company was founded in 2007 by Rajeev Singh and Mike Hilton and has since developed into a leading healthcare consulting firm. Accolade aims to make healthcare simple and affordable for everyone. The company offers a wide range of solutions to its customers. It provides services to employers, insurance companies, and health authorities. Their main focus is on supporting patients and employees in their healthcare. They also offer services to health insurance companies and health authorities. The business model of Accolade involves close collaboration between the customers and the company. Patients are supported by a "Health Assistant," who are trained professionals that help patients make the best decisions regarding their health. Factors such as finding the best providers, medication delivery, clinical tests, and alternative options are considered. Accolade's mission is to improve healthcare for everyone by providing the best solutions. The company has divided itself into several different divisions to offer its services more effectively. The various divisions of Accolade include healthcare consulting, medication management, patient access and health navigation, client support, and health optimization. Accolade has become an important healthcare service provider and has earned a good reputation in the industry. The company is known for providing comprehensive and high-quality services that focus on individual patient care. When it comes to achieving improvements in care and the entire healthcare system, Accolade is an important partner that helps companies and individuals achieve their goals and lead healthier lives.

Accolade SWOT Analysis

Strengths

Accolade Inc. has several strengths that contribute to its success in the market. These include:

  • Strong brand reputation: Accolade Inc. is widely recognized and respected in the industry.
  • Diverse product portfolio: The company offers a wide range of products, catering to different customer needs.
  • Innovative technology: Accolade Inc. continually invests in research and development, resulting in cutting-edge products and solutions.
  • Strong financial position: The company has a solid financial foundation, allowing it to withstand market fluctuations and invest strategically.
  • Strong customer base: Accolade Inc. has established long-term relationships with a large and loyal customer base.

Weaknesses

Despite its strengths, Accolade Inc. also faces certain weaknesses that may hinder its growth and success:

  • Dependence on key customers: The loss of a major customer could significantly impact the company's financial performance.
  • Limited international presence: Accolade Inc. primarily operates in domestic markets, which may restrict its growth opportunities.
  • Reliance on third-party suppliers: The company relies on external suppliers for certain key components, making it susceptible to supply chain disruptions.
  • High competition: The industry in which Accolade Inc. operates is highly competitive, requiring continuous innovation and differentiation.
  • Dependence on specific market segments: Accolade Inc.'s success depends on specific market segments, making it vulnerable to changes in consumer preferences.

Opportunities

Accolade Inc. can leverage various opportunities to enhance its market position and drive growth:

  • Expansion into new markets: Exploring untapped domestic and international markets can help diversify the company's revenue streams.
  • Technological advancements: The increasing demand for technologically advanced products presents opportunities for Accolade Inc. to develop innovative solutions.
  • Increase in healthcare spending: Rising healthcare expenditures create a favorable environment for Accolade Inc. to offer premium products and services.
  • Partnerships and collaborations: Collaborating with other industry leaders or forming strategic alliances can expand Accolade Inc.'s market reach and capabilities.
  • Changing regulatory landscape: Adapting to evolving regulations and compliance requirements can create opportunities for Accolade Inc. to gain a competitive edge.

Threats

Accolade Inc. faces several threats that pose risks to its business and market position:

  • Intense market competition: The industry is characterized by fierce competition, with numerous players vying for market share.
  • Economic downturns: Economic instability and recessions can impact consumer spending, potentially leading to a decline in demand for Accolade Inc.'s products.
  • Rapid technological advancements: Failure to keep pace with technological changes may render Accolade Inc.'s products obsolete or less desirable in the market.
  • Changing healthcare policies: Shifts in healthcare policies and regulations may affect reimbursement rates or market access for Accolade Inc.'s products.
  • Supply chain disruptions: Disruptions in the supply chain, such as natural disasters or geopolitical issues, can disrupt production and compromise product availability.

Accolade Segments

Accolade Revenue by Segment

  • Max

Access fees
Usage-based fees
Details
Date
Access fees
Usage-based fees
Jan 1, 2024
300.49 M USD
113.80 M USD

Accolade Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Accolade historical P/E ratio, EBIT multiple, and P/S ratio

Accolade annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Accolade shares outstanding

The number of shares of Accolade was 80.65 M in 2025. This indicates how many shares Accolade is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
51.58 M Stocks
Jan 1, 2021
71.49 M Stocks
Jan 1, 2022
71.23 M Stocks
Jan 1, 2023
76.14 M Stocks
Jan 1, 2024
80.65 M Stocks
Jan 1, 2025 (e)
80.65 M Stocks
Jan 1, 2026 (e)
80.65 M Stocks
Jan 1, 2028 (e)
80.65 M Stocks

Current Accolade forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy38.89 % (7)
Hold61.11 % (11)
Sell0.00 % (0)
12M Price Target
7.17
Last Price
7.02
Currency
USD
12M Return Potential
2.15 %
LTM Return
0 %

Accolade Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
1/7/2026-0.27USD123.58 MUSD2026 Q3
6/27/2024-0.40USD112.87 MUSD2025 Q1
4/25/2024-0.14USD128.86 MUSD2024 Q4
1/8/2024-0.52USD102.81 MUSD2024 Q3
10/4/2023-0.55USD95.88 MUSD2024 Q2
6/28/2023-0.60USD95.84 MUSD2024 Q1
4/26/2023-0.42USD103.19 MUSD2023 Q4
1/9/2023-0.63USD88.86 MUSD2023 Q3
10/6/2022-0.74USD84.11 MUSD2023 Q2
6/30/2022-0.68USD83.20 MUSD2023 Q1

EESG©

Eulerpool ESG Scorecard© for the Accolade stock

28/100
13
Environment
39
Social
32
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees74
Percentage of women in management
Percentage of Asian employees7.8
Share of Asian management11.7
Percentage of Hispanic/Latino employees10.9
Hispano/Latino Management share6.3
Percentage of Black employees24.1
Black Management Share8.3
Percentage of white employees51.6
White Management Share70.7
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Accolade shareholder structure

% Name
0.26458%
Conestoga Capital Advisors, LLC
Conestoga Capital Advisors, LLC
0.23913%
Jupiter Asset Management Ltd.
Jupiter Asset Management Ltd.
0.07570%
McHugh (Colin)
McHugh (Colin)
0.01874%
Sygnia Asset Management
Sygnia Asset Management
0.01314%
Oracle Alpha Inc.
Oracle Alpha Inc.
0.01287%
Kent (Cindy)
Kent (Cindy)
...

Accolade Executives and Management Board

SM

Ms. Snezana Mahon

President

GT

Mr. Glen Tullman

Chief Executive Officer

SP

Ms. Stephanie Peng

Chief Financial Officer

KB

Mr. Kristen Bruzek

Executive Vice President, Chief Service Delivery Officer

PK

Mr. Praful Kaul

Chief Technology Officer

Accolade Supply Chain

Accolade Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
8 companies
#Name1M3M6M1Y2YTrend
1
0.48
-0.10
0.18
0.78
2
0.47
0.71
0.89
-0.30
3
0.39
-0.48
-0.66
0
4
Premier A
Supplier
0.16
-0.46
0.58
-0.04
5
Amazon.com
Supplier
0.18
0.42
0.65
0.59

Frequently asked questions about Accolade

Accolade Inc operates as a healthcare technology and services company. The company's business model is based on providing personalized health and benefits solutions to individuals and their families. Accolade's services include healthcare navigation, behavioral health support, benefits advisory, and chronic condition management. By combining technology and human touch, Accolade aims to simplify and improve access to healthcare for its clients. Through their platform, Accolade Inc aims to empower individuals in making informed healthcare decisions, managing their health conditions, and optimizing their overall well-being. Accolade Inc strives to enhance healthcare outcomes and reduce costs for both individuals and employers.

All fundamentals and in-depth analysis of Accolade

Our stock analysis for Accolade stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Accolade. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.